BACKGROUND: Pembrolizumab monotherapy is a standard-of-care treatment for the first-and second-line treatment of advanced non-small cell lung cancer with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) values 50% and 1%, respectively. PD-L1 testing with the PD-L1 immunohistochemistry (IHC) 22C3 pharmDx companion assay has been validated on tumor tissue with the Dako Autostainer Link 48 (ASL48). 22C3 anti-PD-L1 antibody-based laboratorydeveloped tests (LDTs) compatible with other autostainers and cytology samples are essential to support pembrolizumab treatment decisions across institutions globally. METHODS: ASL48 and BenchMark Ultra LDTs were optimized for the evaluation of cytology samples through comparisons with cell lines with known PD-L1 expression levels (strong, moderate, and negative). The PD-L1 TPS was then evaluated for 70 paired biopsy and cytology samples (bronchial washes, n 5 40; pleural effusions, n 5 30) with these LDTs. Biopsy and cytology LDT TPS values were also compared with a subset of biopsy samples (n 5 37) evaluated with the PD-L1 IHC 22C3 pharmDx assay on the ASL48. RESULTS: Intraclass correlation coefficients of 0.884 to 0.898 were observed for biopsy samples versus cytology samples with the ASL48 and BenchMark Ultra LDTs. Concordance was high, regardless of the TPS cut point (<1% vs 1% and <50% vs 50%), sample type (pleural effusion vs bronchial wash), or tumor histology (adenocarcinoma vs squamous cell carcinoma). Concordance was high for each LDT versus the PD-L1 IHC 22C3 pharmDx assay. CONCLUSIONS: ASL48 and BenchMark Ultra 22C3 antibody concentrate-based LDTs have been validated for PD-L1 testing in cytology samples, and they will support reliable, high-quality PD-L1 testing across regions globally. Cancer Cytopathol 2018;126:264-74.
INTRODUCTION
Monoclonal antibodies directed against programmed death 1 and programmed death-ligand 1 (PD-L1) have produced remarkable improvements in clinical outcomes for patients with advanced non-small cell lung cancer (NSCLC) and have become standard-of-care treatments. 1 Among these agents, pembrolizumab-an immunotherapy that blocks the interaction between programmed death 1 and its ligands, PD-L1 and PD-L2-has been shown to improve overall survival in comparison with docetaxel as second-line therapy for patients with advanced NSCLC and a PD-L1 expression tumor proportion score (TPS) 1% 2 and to improve progression-free survival and overall survival in comparison with platinum-based chemotherapy for patients with previously untreated advanced NSCLC with a PD-L1 TPS 50%. 3 These data led to approval for the first-and second-line use of pembrolizumab monotherapy from the European Medicines Agency and the US Food and Drug Administration. 4, 5 Importantly, because the first-and second-line indications for pembrolizumab in metastatic NSCLC require PD-L1 expression TPS values 50% and 1%, respectively, the proper identification of patients who are eligible for treatment relies on high-quality and reproducible evaluations of PD-L1 tumor expression by pathologists. The PD-L1 immunohistochemistry (IHC) 22C3 pharmDx kit was used on the Autostainer Link 48 (ASL48; Agilent Technologies, Carpinteria, California) in the previously outlined pivotal pembrolizumab clinical trials, and it has been approved as a companion diagnostic assay by the US Food and Drug Administration and has been CE-marked in Europe for the evaluation of tumor PD-L1 expression. [4] [5] [6] Additional options for the reliable and high-quality evaluation of PD-L1 TPS values with laboratory-developed tests (LDTs) that use a 22C3 antibody concentrate (reference M365329; Agilent Technologies) on widely used autostainers are essential for supporting clinical decision making regarding patient eligibility for pembrolizumab treatment across institutions globally. We have previously reported the optimization of 22C3 antibody concentrate-based LDTs for PD-L1 testing on tumor tissue samples, and we demonstrated their compatibility with the ASL48 and an additional IHC platform, the BenchMark Ultra autostainer (Ventana, Tucson, Arizona). 7 Another consideration is that the PD-L1 IHC 22C3 pharmDx assay is approved for use on formalinfixed, paraffin-embedded (FFPE) tumor tissue, and it was validated in samples obtained from resections, core-needle biopsies, and bronchoscopies that yielded 100 cells. 6, 8 In the current report, we describe further optimization of our 22C3 antibody concentrate-based LDTs with cytology samples. Because the diagnosis of NSCLC in 30% to 50% of patients is based solely on cytology samples, 8, 9 many institutions would benefit from the ability to use these specimens for reliable PD-L1 testing. Cytology specimens are most often obtained from transthoracic computed tomography-guided fine-needle biopsies, bronchoscopy-guided fine-needle aspiration (FNA), endobronchial ultrasound-guided FNA, and bronchoscopic brushings or washes. 10, 11 Recent evidence suggests that using such sample types for PD-L1 testing is a viable approach. 9, 12, 13 However, there is currently no validated companion diagnostic test available for evaluating PD-L1 expression in cytology samples. Thus, reliable LDTs using a 22C3 antibody concentrate that are compatible with these types of samples would further facilitate high-quality PD-L1 testing. Here we describe an extension of the initial study that established 22C3 antibody concentrate-based LDTs for tumor tissue PD-L1 testing on the ASL48 and BenchMark Ultra autostainers, 7 both of which demonstrated almost 100% concordance with the reference PD-L1 IHC 22C3 pharmDx assay using the ASL48 platform. 7 The objective of the current study was to optimize these LDTs for use with cytology samples obtained from bronchial washes and pleural effusions. Specifically, we compared PD-L1 TPS values for tumor tissue and cytology samples stained with 22C3 antibody concentrate-based LDTs on the ASL48 and BenchMark Ultra platforms, and then we compared TPS values from the LDT stains on each of these sample types with a subset of biopsy samples stained with the reference PD-L1 IHC 22C3 pharmDx assay.
MATERIALS AND METHODS

Clinical Samples
Tumor tissue and paired cytology samples were obtained from 70 patients undergoing treatment in the Department of Pulmonary Medicine and Thoracic Surgery at Pasteur Hospital (Côte d'Azur University, Nice, France) between July 2014 and November 2016. All study procedures were performed in compliance with the Declaration of Helsinki; the protocol was approved by the local ethics committee; and all patients provided written informed consent for the collection, storage, and use of samples. The clinical outcomes of the patients who contributed samples were not evaluated in this study. The 2 sample types (ie, FFPE bronchial biopsy samples and cytology samples from pleural effusions or bronchial washes) were evaluated together in pairs. Tissue samples with a preserved tumor morphology and 100 cancer cells present in each section were eligible for inclusion in the study. Only cytology samples with paired biopsy or surgical resection specimens were included, and the histologic and immunophenotypic subtype of NSCLC in the biopsy/surgical resection specimens served as the reference diagnosis. Forty-eight samples were PD-L1 22C3 Cytology-Based LDTs in NSCLC/Ilie et al
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April 2018 adenocarcinomas, and 22 were squamous cell carcinomas. Forty samples were obtained from bronchial washes, and 30 samples were obtained from pleural effusions. The tumor cellularity measurement was performed manually on live images collected with an Olympus BX53 microscope (Olympus America, Inc, Center Valley, Pennsylvania) and with the cellSens 1.16 software measurement tools (Olympus). The number of tumor cells in cytology samples varied from 6 to 768 for the 70 specimens tested with the ASL48 LDT and from 9 to 825 for the 70 specimens tested with the Ventana LDT. Tumor samples obtained from patients with epidermal growth factor receptor mutations, anaplastic lymphoma kinase translocations, or other genetic alterations were not excluded.
Tumor tissue specimens were prepared as previously described. 7 The preparation of the cytology samples differed on the basis of the type of specimen. Pleural effusion fluids were centrifuged unfixed; cell pellets were prepared by the addition of 4 drops of Cytoblock reagent (Thermo Scientific, Illkirch, France) and were then fixed in 10% neutral buffered formalin (NBF) and paraffin-embedded. Bronchial washings, collected in a preservative solution (NovaPrep HQ1; Novacyt, V elizy-Villacoublay, France), were transferred to a 50-mL Falcon tube with DL-Dithiothreitol powder (Sigma-Aldrich, Saint-Quentin-Fallavier, France), shaken for 30 minutes, and then centrifuged at 1500 rpm for 5 minutes at room temperature. The supernatant was then removed, 10 mL of a mucolytic solution (Novacyt) was added, and the sample was then further shaken for 20 minutes and centrifuged at 1500 rpm for 5 minutes at room temperature. The cell pellets were deposited in NovaPrep tubes (Novacyt) containing 10% NBF and either were processed for cytology staining with an NPS 50 automated instrument (NovaPrep Processor System; Novacyt) or were fixed in 10% NBF and paraffin-embedded for cell block preparation. Histologic sections from cell blocks were prepared and stained with hematoxylin and eosin.
PD-L1 Staining Assays
PD-L1 expression was evaluated on tumor tissue with LDTs using a 22C3 antibody concentrate (reference M365329; Agilent Technologies) on 3 commercially available autostainers, as previously described. 7 LDTs were successfully established on the ASL48 and BenchMark Ultra systems by comparison with the reference (or gold-standard) PD-L1 IHC 22C3 pharmDx assay on the Dako ASL48 platform.
7
The same protocols were tested on paired cytology samples, which were also compared with the PD-L1 IHC 22C3 pharmDx assay on the ASL48 platform. 
Evaluation of TPSs Using 22C3 Assays on Tumor Tissue and Cytology Samples
The PD-L1 TPS was evaluated in 70 paired tumor tissue samples and cell blocks obtained from bronchial washes (n 5 40) and pleural effusions (n 5 30) with the ASL48 and BenchMark Ultra LDTs. PD-L1 expression was also determined in 37 biopsy specimens with the PD-L1 IHC 22C3 pharmDx assay. 6 The evaluation of the PD-L1 TPS was performed by 2 senior lung pathologists (M.I. and P.H.). The TPS was calculated as the percentage of PD-L1-positive cells based on the total number of viable tumor cells in the specimen. Tumor cells with complete or partial cell membrane staining (1 1 to 3 1 intensity) were counted as PD-L1-positive. The 2 pathologists evaluated samples independently and were unaware of the platforms used for staining.
All samples stained on a given platform were evaluated at the same time. The scoring of samples stained on different platforms was performed independently at different times. In addition, between each analysis on a given autostainer, the order of samples was randomly rearranged by the technicians preparing the specimens.
Statistical Analysis
The concordance of PD-L1 TPS values was evaluated between tumor tissue and cytology samples stained with the 22C3 antibody concentrate-based LDTs on the ASL48 and BenchMark Ultra platforms. It was determined that a sample size of 70 was needed to ensure an error margin near or less than 10%. Concordance was also evaluated between scores from tumor tissue and cytology samples stained with the LDTs and those from biopsy samples stained with the PD-L1 IHC 22C3 pharmDx assay (reference assay; n 5 37).
The TPS was analyzed as continuous and categorical variables separately. Categorical comparisons dichotomized positive scores with 2 cut points: positive TPS (1%) and strongly positive TPS (50%). Negative and positive percentage agreements were calculated for the comparisons (with the TPS cut points of 1% and 50%), and 95% confidence intervals were estimated with the 2-sided Wilson score confidence limits. Intraclass correlation coefficients (ICCs) were calculated for TPS raw score comparisons.
RESULTS
Validation of the 22C3 IHC Assays on Cell Lines
The LDTs were validated for the evaluation of cytology samples through the preparation of cell lines with strong PD-L1 expression (NCI-H820), moderate PD-L1 expression (NCI-H226), and negative PD-L1 expression (MCF7) as FFPE cell blocks and then through staining with the ASL48 and BenchMark Ultra LDTs previously developed on tumor tissue (1:50 dilution). 7 Comparisons with the PD-L1 IHC 22C3 pharmDx assay on the ASL48 platform showed overall that lower concentrations of the 22C3 concentrated primary antibody (eg, 
Concordance Between PD-L1 TPS Values for Tumor Tissue and Cytology Samples Evaluated by LDTs
Comparisons of PD-L1 TPS values from biopsy and cytology samples demonstrated consistently high negative and positive percentage agreements with both the ASL48 and BenchMark Ultra LDTs (Table 1 and Fig. 1 ). For both LDTs, the total percentage agreement exceeded 95% for tumor tissue versus cytology samples when it was assessed by either pathologist at TPS cut points of both 1% and 50%. Similarly, ICCs showed high concordance overall when TPS values of tumor tissue and cytology samples were compared ( Table 2 ). The ICCs were 0.884 to 0.898 for biopsy samples versus cytology samples on the ASL48 and BenchMark Ultra LDT platforms. This finding was consistent when it was evaluated by the type of cytology sample (pleural effusion vs bronchial wash) or tumor histology (adenocarcinoma vs squamous cell carcinoma; Table 2 ). A comparison of the PD-L1 scores of the 2 pathologists (M.I. and P.H.) showed high concordance for both sample types with an ICC of 0.997 for tumor tissue samples and an ICC of 1.000 for cytology samples on both platforms. In addition, the wide range of tumor cell numbers in the cytology samples did not appear to influence the evaluation of the TPS on specimens stained with the 22C3 LDTs (Supporting Fig. 3 [see online supporting information]).
Concordance Between the LDTs and PD-L1 IHC 22C3 pharmDx Assay
We found high concordance in TPS values for both tumor tissue and cytology samples stained with either the ASL48 LDT or the BenchMark Ultra LDT in comparison with the PD-L1 IHC 22C3 pharmDx assay (Table 3 and Fig. 2) . The ICCs were 0.999 to 1.000 for biopsy samples and 0.936 to 0.947 for cytology samples when we compared the LDTs with the 37 available biopsy samples stained with the PD-L1 IHC 22C3 pharmDx assay.
Concordance Between Tumor Tissue and Cytology Samples and Between the LDTs and PD-L1 IHC 22C3 pharmDx Assay
Representative micrographs showing concordance between tumor tissue and cytology samples and between the 22C3 LDTs and the PD-L1 IHC 22C3 pharmDx assay for PD-L1 22C3 Cytology-Based LDTs in NSCLC/Ilie et al
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samples with TPS values of 100% and 0% are shown in Figure 3 ; similarly, concordance for samples with TPS values of 50% and 10% is shown in Supporting Figures 4 and 5, respectively (see online supporting information). Overall, there was very little discordance between PD-L1 TPS values on tumor tissue and cytology samples stained with either 22C3 LDT. Evaluations of TPS values of 0% and 1% differed for only 2 of the 70 paired samples, and evaluations of TPS values of <50% and 50% differed for only 3 samples. Figure 4 shows an example of discordant PD-L1 staining, with tumor tissue showing a TPS value of 5% and a pleural effusion cell block showing a TPS value of 90%; PD-L1 staining between the 22C3 LDTs and the PD-L1 IHC 22C3 pharmDx assay was consistent. In contrast, Figure 5 shows positive PD-L1 staining on tumor tissue (TPS of 100%) and no PD-L1 staining on a pleural effusion cell block with 100 tumor cells, and there were consistent results between the 22C3 LDTs.
DISCUSSION
The 22C3 antibody concentrate-based LDTs used in this study were previously established on the ASL48 and BenchMark Ultra platforms with tumor tissue samples. 7 In the current study, we optimized these protocols to determine PD-L1 expression in cytology specimens, and we observed high concordance (approximately 90%) in the evaluation of TPS values for biopsy and cytology samples with these 22C3 antibody concentrate LDTs at both TPS cut points evaluated. Although a small number of TPS Original Article evaluations were found to be discordant between biopsy and cytology samples, our results were robust because concordance remained high, regardless of the TPS cut point (<1% vs 1% and <50% vs 50%), sample type (pleural effusion vs bronchial wash, with bronchial washes having slightly higher concordance), or tumor histology (adenocarcinoma vs squamous cell carcinoma, with squamous cell carcinomas having slightly higher concordance). In addition, TPS values on biopsy and cytology samples stained with the 22C3 LDTs were concordant with the reference PD-L1 IHC 22C3 pharmDx assay in a subgroup of biopsy specimens (n 5 37). Together, these findings support the viability of using cytology samples with a 22C3 antibody concentrate-based LDT to determine NSCLC tumor PD-L1 expression when one is evaluating pembrolizumab treatment eligibility.
These results expand on prior studies that have shown similar PD-L1 TPS values for tissue samples and cytology samples with the PD-L1 IHC 22C3 pharmDx assay. 9, 12 Heymann et al 12 recently demonstrated key support for the feasibility of using cytology samples for PD-L1 testing using the reference pharmDx assay; however, it is notable that only a small number of paired comparisons of cytology and biopsy samples were evaluated (n 5 5). The larger number of paired tumor and cytology samples in our study (n 5 70), combined with the high concordance observed in the TPS evaluations of these samples by 2 separate pathologists, provides important support for the reliability and reproducibility of our results. In addition, because it is impractical for all laboratories to obtain the ASL48 platform for use with the reference assay, our work addresses the critical need for PD-L1 LDTs that can be 
the 22C3 LDT on the ASL48, and (C) the 22C3 LDT on the BenchMark Ultra; on cytology samples (pleural effusions) with a PD-L1 TPS of 100% with (D) the PD-L1 IHC 22C3 pharmDx assay on the ASL48, (E) the 22C3 LDT on the ASL48, and (F) the 22C3 LDT on the BenchMark Ultra; on tumor tissue with a PD-L1 TPS of 0% with (G) the PD-L1 IHC 22C3 pharmDx assay on the ASL48, (H) the 22C3 LDT on the ASL48, and (I) the 22C3 LDT on the BenchMark Ultra; and on cytology samples (pleural effusions) with a PD-L1 TPS of 0% with (J) the PD-L1 IHC 22C3 pharmDx assay on the ASL48, (K) the 22C3 LDT on the ASL48, and (L) the 22C3 LDT on the BenchMark Ultra (magnification 3 20). ASL48 indicates Autostainer Link 48; IHC, immunohistochemistry; LDT, laboratorydeveloped test; NSCLC, non-small cell lung cancer; PD-L1, programmed death-ligand 1; TPS, tumor proportion score.
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used on the more widely available Ventana BenchMark Ultra autostainer. The significance of our results is underscored by the potential practical application of this work across geographic regions that may predominantly use cytology specimens to diagnose NSCLC and may not be equipped with the ASL48 autostainer.
14 A comparison of the 2 pathologists who evaluated samples in this trial showed almost 100% concordance on both 22C3 antibody concentrate LDTs with both tumor tissue and cytology samples. Although it is unclear whether such high concordance between the assays would be reproducible if they were evaluated by multiple pathologists at other institutions, this level of concordance suggests a high likelihood of success with wider use of these LDTs across laboratories, particularly because concordance remained high across potentially influential sample characteristics, such as the level of TPS expression (ie, positive and strongly positive), the type of cytology sample used, and the number of tumor cells in the sample. Notably, we found that a 1:50 dilution of the 22C3 anti-PD-L1 antibody concentrate provided optimal staining of cytology samples. In addition, we do not currently recommend room-temperature drying of samples because this has not yet been validated. Moreover, all cytology samples in our study were fixed in 10% NBF, and the use of other methods was not evaluated. The impact of alcohol-based or other nonformalin fixatives for cell blocks on PD-L1 staining is currently unknown.
A notable limitation of this study is that patients contributing samples were not prospectively treated or followed to evaluate clinical outcomes. Although the technical validation of an assay is essential, the clinical validation of an IHC assay is necessary to definitively show that the selected assay can identify patients who are likely to derive optimal therapeutic benefit from a treatment. 8 The high concordance that we have observed between our LDTs and the reference PD-L1 IHC 22C3 pharmDx assay, which is the approved companion diagnostic, supports the feasibility of using these 22C3 antibody concentrate-based LDTs for determining pembrolizumab treatment eligibility. Limitations with the use of cytology samples should be noted. First, there are currently very limited data available on the use of cytology specimens for PD-L1 testing. In this study, we have evaluated only a subset of possible sample types; thus, additional data that support the feasibility of using other cytology specimens (eg, specimens from fine-needle biopsies, bronchoscopy-guided FNA, endobronchial ultrasound-guided FNA, and bronchial brushes) with 22C3 antibody concentrate-based LDTs are needed. It should also be emphasized that careful interpretation of PD-L1 staining in cytology samples is warranted because of the presence of immune cells, particularly macrophages, which are found in large numbers in pleural effusions. If these samples are evaluated without reference to a hematoxylin and eosin slide or, in some cases, complementary stains to assess immune cells such as macrophages or lymphocytes, the PD-L1 staining might be misinterpreted as positive tumor cell PD-L1 expression, even though tumor cells adjacent to the macrophage infiltrate have no PD-L1 expression, as shown in Supporting Figure 6 (see online supporting information) and previously reported. 15 In addition, although it is necessary to have 100 viable tumor cells present in tissue specimen slides to determine the percentage of PD-L1-stained cells, 8 there is no established minimum requirement for the number of tumor cells in cytology specimens. PD-L1 staining and quantitation should be technically feasible in principle as long as appropriate protocols and quality-control measures are being used. Although cytology samples can have poor cellularity and it may be difficult on occasion to obtain 100 viable tumor cells in these specimens, notably, 54% to 60% of cytology samples tested with the LDTs in our study had 100 tumor cells, and 74% to 76% had 50 tumor cells.
In conclusion, our results support the use of 22C3 antibody concentrate-based LDTs to evaluate PD-L1 expression in cytology samples stained on 2 commonly used IHC platforms. These validated 22C3 antibody concentrate LDTs will significantly expand the number of laboratories that can offer reliable, high-quality PD-L1 testing across geographic regions that primarily use cytology samples for the diagnosis of NSCLC. 
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